EXCLUSIVE: U.S. FDA Posts Import Alert For Ranbaxy’s Mohali Site; Adds Mohali To Consent Decree
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the United States in a move that could impact the company’s chances for approval of valsartan.